+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Azilect"

Parkinson's Disease: Global Drug Forecast and Market Analysis to 2026 - Product Thumbnail Image

Parkinson's Disease: Global Drug Forecast and Market Analysis to 2026

  • Report
  • May 2018
  • 127 Pages
  • Global
From
Parkinson's Disease by Major Markets - Size, Trends and Drug Forecast including Epidemiology, Disease Management, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Pipeline Analysis to 2029 - Product Thumbnail Image

Parkinson's Disease by Major Markets - Size, Trends and Drug Forecast including Epidemiology, Disease Management, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Pipeline Analysis to 2029

  • Drug Pipelines
  • July 2023
  • 139 Pages
  • Global
From
Azilect - Product Thumbnail Image

Azilect

  • Report
  • June 2018
  • 16 Pages
  • Global
From
Azilect - API Insight, 2022 - Product Thumbnail Image

Azilect - API Insight, 2022

  • Drug Pipelines
  • January 2022
  • 30 Pages
  • Global
From
  • 4 Results (Page 1 of 1)
Loading Indicator

Azilect is a brand of Central Nervous System (CNS) drugs used to treat Parkinson's disease. It is a monoamine oxidase type B (MAO-B) inhibitor, which works by blocking the breakdown of dopamine in the brain. This helps to reduce the symptoms of Parkinson's, such as tremors, stiffness, and difficulty with movement. Azilect is typically prescribed in combination with other medications, such as levodopa, to maximize its effectiveness. The Azilect market is a growing segment of the CNS drug market, with a focus on treating Parkinson's disease. It is a highly competitive market, with a number of different companies offering their own versions of the drug. Companies in the Azilect market include Teva Pharmaceuticals, Mylan, and Sun Pharmaceuticals. Show Less Read more